NASDAQ:EMBC Embecta (EMBC) Stock Forecast, Price & News $15.17 -0.31 (-2.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$15.16▼$15.6150-Day Range$15.17▼$22.1752-Week Range$15.16▼$36.64Volume488,284 shsAverage Volume627,993 shsMarket Capitalization$869.24 millionP/E Ratio18.73Dividend Yield3.96%Price Target$16.00 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Embecta MarketRank™ ForecastAnalyst RatingSell1.00 Rating ScoreUpside/Downside5.5% Upside$16.00 Price TargetShort InterestBearish7.72% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$409,371 Bought Last QuarterProj. Earnings Growth-27.46%From $2.84 to $2.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.36 out of 5 starsMedical Sector924th out of 968 stocksSurgical & Medical Instruments Industry85th out of 90 stocks 0.5 Analyst's Opinion Consensus RatingEmbecta has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Embecta has a forecasted upside of 5.5% from its current price of $15.17.Amount of Analyst CoverageEmbecta has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.72% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Embecta has recently increased by 19.67%, indicating that investor sentiment is decreasing significantly. Previous Next 3.3 Dividend Strength Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 3.81%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 74.07%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 29.13% next year. This indicates that Embecta will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EMBC. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for EMBC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Embecta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have bought more of their company's stock than they have sold. Specifically, they have bought $409,371.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.22% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Embecta are expected to decrease by -27.46% in the coming year, from $2.84 to $2.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 18.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.52.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 18.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.13. Previous Next See Top Rated MarketRank™ Stocks Here About Embecta (NASDAQ:EMBC) StockEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More EMBC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMBC Stock News HeadlinesSeptember 12, 2023 | americanbankingnews.comEmbecta (NASDAQ:EMBC) Shares Gap Up Following Insider Buying ActivitySeptember 6, 2023 | finance.yahoo.comembecta to Participate at the Morgan Stanley 21st Annual Healthcare ConferenceSeptember 22, 2023 | Stansberry Research (Ad)Investing Legend Warns: NVIDIA is a "Delusion"Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.August 11, 2023 | finance.yahoo.comEmbecta's (NASDAQ:EMBC) Dividend Will Be $0.15August 10, 2023 | markets.businessinsider.comEmbecta Corporation (EMBC) Gets a Sell from Bank of America SecuritiesAugust 8, 2023 | msn.comEmbecta Corp. (EMBC) Beats Q3 Earnings and Revenue EstimatesAugust 8, 2023 | finance.yahoo.comEmbecta Corp. Reports Third Quarter Fiscal 2023 Financial ResultsJuly 30, 2023 | es.investing.comEmbecta Corp (EMBC)September 22, 2023 | Stansberry Research (Ad)Investing Legend Warns: NVIDIA is a "Delusion"Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.July 23, 2023 | seekingalpha.comEmbecta: Slow Growth Shows Why The Valuation Is So LowJuly 21, 2023 | seekingalpha.comEmbecta: Mammoth Effort Needed To Get Investors Over The Line, Reiterate HoldJuly 11, 2023 | finance.yahoo.comembecta to Report Fiscal Third Quarter 2023 Financial ResultsJune 30, 2023 | finance.yahoo.comThe Market Doesn't Like What It Sees From Embecta Corp.'s (NASDAQ:EMBC) Revenues YetJune 10, 2023 | fool.comEmbecta (NASDAQ: EMBC.V)May 20, 2023 | finance.yahoo.comJust Four Days Till Embecta Corp. (NASDAQ:EMBC) Will Be Trading Ex-DividendMay 15, 2023 | finance.yahoo.comembecta to Participate in Investor ConferencesMay 15, 2023 | finance.yahoo.comUPDATE -- embecta to Participate in Investor ConferencesMay 15, 2023 | markets.businessinsider.comMorgan Stanley Maintains Underweight Rating for Embecta: Here's What You Need To KnowMay 15, 2023 | finance.yahoo.comEmbecta Corp. (EMBC) Recently Broke Out Above the 50-Day Moving AverageMay 15, 2023 | finance.yahoo.comEmbecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for InvestorsMay 14, 2023 | msn.comEmbecta (EMBC) Declares $0.15 DividendMay 13, 2023 | finance.yahoo.comEmbecta Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2023 | marketwatch.com8-K: Embecta Corp.May 12, 2023 | marketwatch.comembecta and Tidepool partner to develop automated insulin delivery system for people with Type 2 diabetesMay 12, 2023 | markets.businessinsider.comBTIG Keeps Their Hold Rating on Embecta Corporation (EMBC)May 12, 2023 | seekingalpha.comEmbecta Corp. (EMBC) Q2 2023 Earnings Call TranscriptMay 12, 2023 | msn.comEmbecta: Q2 Earnings InsightsSee More Headlines Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Company Calendar Last Earnings8/08/2023Ex-Dividend for 9/13 Dividend8/24/2023Dividend Payable9/13/2023Today9/22/2023Fiscal Year End9/30/2023Next Earnings (Estimated)12/18/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees1,900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+5.5%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.81 Trailing P/E Ratio18.73 Forward P/E Ratio5.34 P/E GrowthN/ANet Income$223.60 million Net Margins4.24% Pretax Margin6.57% Return on Equity-21.04% Return on Assets14.89% Debt Debt-to-Equity RatioN/A Current Ratio2.04 Quick Ratio1.60 Sales & Book Value Annual Sales$1.13 billion Price / Sales0.77 Cash Flow$5.29 per share Price / Cash Flow2.87 Book Value($15.41) per share Price / Book-0.98Miscellaneous Outstanding Shares57,300,000Free Float57,178,000Market Cap$869.24 million OptionableOptionable Beta0.49 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Devdatt Kurdikar (Age 55)Pres, CEO & Director Comp: $1.91MMr. Jacob P. Elguicze (Age 50)Sr. VP & CFO Comp: $971.06kMr. Jeffrey Z. Mann (Age 50)Sr. VP, Gen. Counsel, Head of Corp. Devel. & Corp. Sec. Comp: $910.73kMr. Shaun Curtis (Age 53)Sr. VP of Global Manufacturing & Supply Chain Comp: $691.46kMr. Brian R. Capone (Age 48)VP, Chief Accounting Officer & Corp. Controller Ms. Colleen Riley (Age 58)Sr. VP & Chief Technology Officer Mr. Pravesh KhandelwalVP & Head of Investor RelationsMs. Ginny BlockiSr. VP of Global Marketing & Product ManagementMr. Tom Blount (Age 49)Sr. VP & Pres of North America Mr. Slobodan Radumilo (Age 52)Sr. VP & Pres of International More ExecutivesKey CompetitorsMiMedx GroupNASDAQ:MDXGTreace Medical ConceptsNASDAQ:TMCISI-BONENASDAQ:SIBNBeauty HealthNASDAQ:SKINOrthoPediatricsNASDAQ:KIDSView All CompetitorsInsiders & InstitutionsBarclays PLCBought 10,911 shares on 9/21/2023Ownership: 0.092%David F MelcherBought 6,233 shares on 9/8/2023Total: $98,294.41 ($15.77/share)ST Germain D J Co. Inc.Bought 4,196 shares on 9/7/2023Ownership: 0.007%Comerica BankBought 130,150 shares on 8/22/2023Ownership: 0.227%Virginia Retirement Systems ET ALBought 23,200 shares on 8/22/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions EMBC Stock - Frequently Asked Questions Should I buy or sell Embecta stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" EMBC shares. View EMBC analyst ratings or view top-rated stocks. What is Embecta's stock price forecast for 2023? 1 equities research analysts have issued 12 month price targets for Embecta's stock. Their EMBC share price forecasts range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 5.5% from the stock's current price. View analysts price targets for EMBC or view top-rated stocks among Wall Street analysts. How have EMBC shares performed in 2023? Embecta's stock was trading at $25.29 at the start of the year. Since then, EMBC stock has decreased by 40.0% and is now trading at $15.17. View the best growth stocks for 2023 here. Are investors shorting Embecta? Embecta saw a increase in short interest in August. As of August 31st, there was short interest totaling 4,380,000 shares, an increase of 19.7% from the August 15th total of 3,660,000 shares. Based on an average trading volume of 648,100 shares, the days-to-cover ratio is currently 6.8 days. Currently, 7.7% of the company's stock are sold short. View Embecta's Short Interest. When is Embecta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, December 18th 2023. View our EMBC earnings forecast. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) issued its earnings results on Tuesday, August, 8th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.23. The business had revenue of $286.10 million for the quarter, compared to the consensus estimate of $275.07 million. Embecta had a negative trailing twelve-month return on equity of 21.04% and a net margin of 4.24%. The business's revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 earnings per share. How often does Embecta pay dividends? What is the dividend yield for Embecta? Embecta declared a quarterly dividend on Tuesday, August 8th. Shareholders of record on Friday, August 25th will be paid a dividend of $0.15 per share on Wednesday, September 13th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date is Thursday, August 24th. Read our dividend analysis for EMBC. What ETFs hold Embecta's stock? ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD).Invesco S&P SmallCap Health Care ETF (PSCH). Is Embecta a good dividend stock? Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 3.81%. The dividend payout ratio is 74.07%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 29.13% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for EMBC. What guidance has Embecta issued on next quarter's earnings? Embecta updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $2.75-$2.80 for the period, compared to the consensus earnings per share estimate of $1.69. The company issued revenue guidance of $1.11 billion-$1.11 billion, compared to the consensus revenue estimate of $1.11 billion. What is Embecta's stock symbol? Embecta trades on the NASDAQ under the ticker symbol "EMBC." Who are Embecta's major shareholders? Embecta's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.85%), Yacktman Asset Management LP (4.58%), State Street Corp (4.26%), Geode Capital Management LLC (2.06%), Krensavage Asset Management LLC (1.87%) and Bank of New York Mellon Corp (1.73%). Insiders that own company stock include David F Melcher, Devdatt Kurdikar, Jacob Elguicze and Jeffrey Z Mann. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Embecta's stock price today? One share of EMBC stock can currently be purchased for approximately $15.17. How much money does Embecta make? Embecta (NASDAQ:EMBC) has a market capitalization of $869.24 million and generates $1.13 billion in revenue each year. The company earns $223.60 million in net income (profit) each year or $0.81 on an earnings per share basis. How many employees does Embecta have? The company employs 1,900 workers across the globe. How can I contact Embecta? The official website for the company is www.embecta.com. The company can be reached via phone at 201-847-6880 or via email at investor.relations@embecta.com. This page (NASDAQ:EMBC) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.